AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21248332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterin
Number of subjects: 160
Study 21248332 — intervention group
Group type: COMPARATOR
Intervention: Control M. gallisepticum
Number of subjects: 160
Study 21248332 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 160
Study 19283449 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted body weight (ABW) dosing of enoxaparin
Number of subjects: 61
Study 19283449 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of enoxaparin
Number of subjects: 61
Study 16715020 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack with abdominal support
Number of subjects: 20
Study 16715020 — intervention group
Group type: COMPARATOR
Intervention: No abdominal support
Number of subjects: 20
Study 16211988 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg orally 3 hours before and 3 hours after the procedure
Number of subjects: 61
Study 16211988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16211988 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 61
Study 12439778 — intervention group
Group type: COMPARATOR
Intervention: 80 Hz electrical stimulation
Number of subjects: 10
Study 12439778 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz electrical stimulation
Number of subjects: 10
Study 9856543 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (10 mg x kg(‐1))
Number of subjects: 11
Study 9856543 — intervention group
Group type: COMPARATOR
Intervention: Noncaffeine ingestion (control)
Number of subjects: 11
Study 8929239 — intervention group
Group type: EXPERIMENTAL
Intervention: GE uncrushed (120 mg myrtol standardized)
Number of subjects: 20
Study 8929239 — intervention group
Group type: COMPARATOR
Intervention: GE crushed (120 mg myrtol standardized)
Number of subjects: 20
Study 8929239 — intervention group
Group type: EXPERIMENTAL
Intervention: GF uncrushed (300 mg myrtol standardized)
Number of subjects: 20
Study 8929239 — intervention group
Group type: COMPARATOR
Intervention: GF crushed (300 mg myrtol standardized)
Number of subjects: 20
Study 2191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin administered simultaneously with heparin infusion
Number of subjects: 0
Study 2191783 — intervention group
Group type: COMPARATOR
Intervention: Heparin without warfarin therapy
Number of subjects: 0
Study 419977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine eyedrops (2% solution four times daily)
Number of subjects: 16
Study 419977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocusert P-40 (constant and continuous supply of pilocarpine)
Number of subjects: 16
Study 31878824 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-contingent gait training for 12 weeks
Number of subjects: 30
Study 31878824 — intervention group
Group type: COMPARATOR
Intervention: Control music group received 6 weeks of noncontingent music walking followed by 6 weeks of music-contingent training
Number of subjects: 30
Study 29153992 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation intentions (n=18)
Number of subjects: 35
Study 29153992 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=17)
Number of subjects: 35
Study 27507403 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene-based composite mesh
Number of subjects: 60
Study 27507403 — intervention group
Group type: COMPARATOR
Intervention: Standard polypropylene mesh
Number of subjects: 60
Study 25389283 — intervention group
Group type: EXPERIMENTAL
Intervention: ZRS >3
Number of subjects: 845
Study 25389283 — intervention group
Group type: EXPERIMENTAL
Intervention: log NT-proBNP
Number of subjects: 845
Study 25389283 — intervention group
Group type: EXPERIMENTAL
Intervention: ZRS
Number of subjects: 845
Study 25389283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ZRS/NT-proBNP
Number of subjects: 845
Study 25389283 — intervention group
Group type: EXPERIMENTAL
Intervention: ZRS ≥2 and NT-proBNP ≥200 pg/mL
Number of subjects: 845
Study 25389283 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up between 48 hours and 10 days
Number of subjects: 845
Study 22996693 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR1/2 allosteric inhibitor reparixin
Number of subjects: 0
Study 22996693 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic and pharmacological blockade of the CXCL1-CXCR1/2 axis
Number of subjects: 0
Study 20462143 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + HBO2
Number of subjects: 20
Study 20462143 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 20
Study 18662188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac echo-guided double transseptal access
Number of subjects: 45
Study 18662188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antral isolation (PVAI)
Number of subjects: 45
Study 18662188 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term recurrence of atrial fibrillation
Number of subjects: 45
Study 18662188 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term recurrence of atrial fibrillation
Number of subjects: 45
Study 18662188 — intervention group
Group type: COMPARATOR
Intervention: Perioperative complications
Number of subjects: 45
Study 18662188 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial communication at 3 months
Number of subjects: 45
Study 15716162 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery in ideomotor apraxia patients
Number of subjects: 19
Study 15716162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions in the intraparietal sulcus
Number of subjects: 19
Study 15716162 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 19
Study 15716162 — intervention group
Group type: COMPARATOR
Intervention: Non-apraxic stroke patients
Number of subjects: 19
Study 12017346 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan (10 to 120 mg)
Number of subjects: 0
Study 12017346 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan (30 to 90 mg)
Number of subjects: 0
Study 12017346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10568079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Assistant Communication Skills Program (NACSP)
Number of subjects: 2
Study 10568079 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (UC)
Number of subjects: 2
Study 8602179 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (50 mg on alternate days)
Number of subjects: 22071
Study 1751651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorazepam as oral premedication (n = 25)
Number of subjects: 50
Study 1751651 — intervention group
Group type: COMPARATOR
Intervention: No premedication (n = 25)
Number of subjects: 50
Study 7040131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigason
Number of subjects: 0
Study 7040131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30388595 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus Plantarum 299v (LP299v) with SSRI, n=40
Number of subjects: 79
Study 30388595 — intervention group
Group type: COMPARATOR
Intervention: Placebo with SSRI, n=39
Number of subjects: 79
Study 30195882 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplement (1000 mg, twice daily for 12 weeks)
Number of subjects: 80
Study 30195882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27186859 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25OHD levels measured
Number of subjects: 540
Study 24930178 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-manual distraction
Number of subjects: 0
Study 24930178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-audio distraction
Number of subjects: 0
Study 24930178 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous distraction condition
Number of subjects: 0
Study 22169398 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended fluid intake (mean amount 2427 ml)
Number of subjects: 465
Study 22169398 — intervention group
Group type: COMPARATOR
Intervention: Low fluid intake (mean amount 1625 ml)
Number of subjects: 465
Study 19765674 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day for 4 weeks, then 40 mg/day for 4 weeks)
Number of subjects: 54
Study 19765674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19765674 — intervention group
Group type: COMPARATOR
Intervention: Citalopram vs Placebo
Number of subjects: 54
Study 19765674 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 54
Study 16959466 — intervention group
Group type: EXPERIMENTAL
Intervention: Video information combined with individualized information sessions
Number of subjects: 109
Study 16959466 — intervention group
Group type: COMPARATOR
Intervention: Standardized information without video
Number of subjects: 109
Study 15793869 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HBsAg-loaded dendritic cells (DCs)
Number of subjects: 19
Study 15793869 — intervention group
Group type: EXPERIMENTAL
Intervention: DCs and lamivudine
Number of subjects: 19
Study 12060531 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral administration of leflunomide (20 mg, 40 mg, 60 mg)
Number of subjects: 24
Study 12060531 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated oral administration of leflunomide (20 mg/d for 30 days)
Number of subjects: 24
Study 10199110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5 mg
Number of subjects: 76
Study 10199110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg
Number of subjects: 76
Study 10199110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 15 mg
Number of subjects: 76
Study 10199110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 76
Study 10199110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 8578014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol inhalation of fenoterol
Number of subjects: 27
Study 8578014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous route of fenoterol
Number of subjects: 27
Study 8578014 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal instillation of fenoterol
Number of subjects: 27
Study 8578014 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhalers (MDI) inhalation of fenoterol
Number of subjects: 27
Study 8578014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol inhalation of 200 micrograms of fenoterol
Number of subjects: 27
Study 1415101 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilson Cook disposable cytology brush
Number of subjects: 78
Study 1415101 — intervention group
Group type: COMPARATOR
Intervention: Other disposable cytology brushes (Microvasive, Mill-Rose, Hobbs)
Number of subjects: 78
Study 4054195 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg once-daily
Number of subjects: 107
Study 4054195 — intervention group
Group type: COMPARATOR
Intervention: pindolol 20 mg slow release (SR) once-daily
Number of subjects: 107
Study 31790481 — intervention group
Group type: COMPARATOR
Intervention: HIV- group (n=162)
Number of subjects: 250
Study 31790481 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PASE
Number of subjects: 250
Study 31790481 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater enjoyment of PA
Number of subjects: 250
Study 31790481 — intervention group
Group type: COMPARATOR
Intervention: HIV- participants
Number of subjects: 250
Study 29710322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 30
Study 29710322 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate
Number of subjects: 30
Study 27117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Glucan Mixture (RGM) 13.2 g/d
Number of subjects: 60
Study 27117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Glucan Mixture (RGM) 6.6 g/d
Number of subjects: 60
Study 27117853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Glucan Mixture (RGM) 3.3 g/d
Number of subjects: 60
Study 27117853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (digestible maltodextrin)
Number of subjects: 60
Study 26307122 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy for proximal plantar fasciitis (type of foot support not specified)
Number of subjects: 70
Study 26307122 — intervention group
Group type: EXPERIMENTAL
Intervention: Biconvexity of the plantar fascia on sonography at presentation
Number of subjects: 70
Study 26307122 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in self-reported pain over the 3-month study period
Number of subjects: 70
Study 23279560 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest compensation for submitting dated time-stamped BrAC videos
Number of subjects: 30
Study 23279560 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) with escalating vouchers for on-time alcohol-negative tests (n-BrAC; <0.02 g/dl)
Number of subjects: 30
Study 21700935 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3b (eGFR 30.0 to 44.9 mL/min/1.73 m²)
Number of subjects: 1312
Study 21700935 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3a (eGFR 45.0 to 59.9 mL/min/1.73 m²)
Number of subjects: 1312
Study 21700935 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (eGFR 60.0 to 89.9 mL/min/1.73 m²)
Number of subjects: 1312
Study 21700935 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (eGFR ≥ 90.0 mL/min/1.73 m²)
Number of subjects: 1312
Study 19086960 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalamine foam 1 g/80 mL/day
Number of subjects: 375
Study 19086960 — intervention group
Group type: COMPARATOR
Intervention: mesalamine liquid enema 1 g/100 mL/day
Number of subjects: 375
Study 17238390 — intervention group
Group type: EXPERIMENTAL
Intervention: ATHENA advisories
Number of subjects: 46
Study 17238390 — intervention group
Group type: COMPARATOR
Intervention: Quality-assurance algorithms
Number of subjects: 46
Study 14996064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroatranol 5 p.p.m. solution applied for 14 days
Number of subjects: 23
Study 14996064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroatranol 25 p.p.m. solution applied for additional 14 days if no reaction to 5 p.p.m.
Number of subjects: 23
Study 14996064 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch testing with chloroatranol
Number of subjects: 23
Study 14996064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chloroatranol exposure)
Number of subjects: 23
Study 10723239 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day)
Number of subjects: 29
Study 10723239 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day)
Number of subjects: 29
Study 10723239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 10723239 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 29
Study 9003815 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 9003815 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy
Number of subjects: 0
Study 9003815 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematologic management for hemorrhagic cerebrovascular accident
Number of subjects: 0
Study 9003815 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacuation of the hematoma
Number of subjects: 0
Study 8195911 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated recommendations for scheduling the next visit
Number of subjects: 620
Study 8195911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no computer-generated recommendations)
Number of subjects: 620
Study 3068400 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment (1,000,000 units over 60 min)
Number of subjects: 87
Study 3068400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase administration (120,000‐180,000 units over 60‐90 min)
Number of subjects: 87
Study 3068400 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with regained coronary flow
Number of subjects: 87
Study 3068400 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with persisting coronary occlusion
Number of subjects: 87
Study 3068400 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and intracoronary routes of administration
Number of subjects: 87
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential incisions
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial incisions
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Superonasal quadrant sclerotomies
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferotemporal quadrant sclerotomies
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Superotemporal quadrant sclerotomies
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotomies to the left of the surgeon
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotomies to the right of the surgeon
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas tamponade
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil tamponade
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: No tamponade
Number of subjects: 46
Study 30451184 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial sclerotomies without tamponade
Number of subjects: 46
Study 27455835 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 41
Study 27455835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25420736 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L PEG + bisacodyl 10 mg
Number of subjects: 196
Study 25420736 — intervention group
Group type: COMPARATOR
Intervention: PEG only group (4 L PEG)
Number of subjects: 196
Study 23011562 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine bolus (120 μg)
Number of subjects: 60
Study 23011562 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine infusion (120 μg/min)
Number of subjects: 60
Study 21510583 — intervention group
Group type: EXPERIMENTAL
Intervention: Blend of rice bran oil and safflower oil (80% rice bran oil and 20% safflower oil)
Number of subjects: 73
Study 21510583 — intervention group
Group type: COMPARATOR
Intervention: Control oil (the oil which the patient was using before)
Number of subjects: 73
Study 18797483 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care record ethnicity data
Number of subjects: 665
Study 18797483 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-New Zealand European ethnic group
Number of subjects: 665
Study 18797483 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand European ethnic group
Number of subjects: 665
Study 18797483 — intervention group
Group type: EXPERIMENTAL
Intervention: Maori respondents
Number of subjects: 665
Study 18797483 — intervention group
Group type: EXPERIMENTAL
Intervention: Misclassification impact on Maori, Pacific, and Indian subcontinent peoples
Number of subjects: 665
Study 18797483 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ethnicities
Number of subjects: 665
Study 18797483 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDICT tool with ethnicity data categorised using Statistics New Zealand prioritisation rules
Number of subjects: 665
Study 16213855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook K‐Jet embryo transfer catheter
Number of subjects: 150
Study 16213855 — intervention group
Group type: COMPARATOR
Intervention: Wallace embryo transfer catheter
Number of subjects: 150
Study 12025527 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 313
Study 12025527 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 313
Study 12025527 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 313
Study 8126353 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hour balance training program manipulating sensory inputs from visual, vestibular, and somatosensory systems
Number of subjects: 24
Study 8126353 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 2544119 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate infusion (16.8 +/- 3.0 mg.kg‐1.min‐1)
Number of subjects: 12
Study 2544119 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 to 1.5 vol% enflurane in a nitrous oxide‐oxygen mixture)
Number of subjects: 12
Study 31031097 — intervention group
Group type: EXPERIMENTAL
Intervention: INPUT education program under RCT conditions
Number of subjects: 135
Study 31031097 — intervention group
Group type: EXPERIMENTAL
Intervention: INPUT education program under IT conditions
Number of subjects: 135
Study 31031097 — intervention group
Group type: EXPERIMENTAL
Intervention: INPUT education program under both RCT and IT conditions
Number of subjects: 135
Study 28493293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone for 2 weeks
Number of subjects: 117
Study 25854635 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg/day
Number of subjects: 352
Study 25854635 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 352
Study 25854635 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 2000 mg/day
Number of subjects: 352
Study 25854635 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 352
Study 25854635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 23711549 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 20
Study 23711549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21863617 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of ephedrine (50 mg/500 ml of Ringer solution)
Number of subjects: 40